Resources

Symbiotic.blue, the UK’s newest Techbio company has launched to innovate a next-generation artificial intelligence-driven drug discovery (AIDD) platform by combining the power of generative AI with brain-inspired methodologies. Symbiotic.blue aims to create smarter, multi-targeted therapeutics to tackle complex diseases.

Draig Therapeutics (“Draig”), a clinical-stage company aiming to transform the treatment of neuropsychiatric diseases, today launches from stealth having raised a total of $140 million (£107 million) in the last nine months. The oversubscribed Series A financing was led by Access Biotechnology, with participation from Canaan Partners, SR One, Sanofi Ventures, Schroders Capital along with seed investors SV Health Investors, which co-founded the company, and ICG.

A Scottish clinical development company is redefining early stage development, taking years off the time it takes for new life improving treatments to become available to patients. BDD Pharma Ltd – based at BioCity Glasgow, one of two Pioneer Group sites in Scotland – has also developed its own, in-house technologies. One of them - OralogiK™ - is a unique patented drug delivery tablet system that enables drugs to be released inside the body at the optimum time, hours after taking the tablets.

The UK’s Minster of State for Science, Research, and Innovation, Lord Patrick Vallance, London & Partners’ CEO, Laura Citron OBE, and Steve Bates OBE, CEO of the UK Bioindustry Association (BIA), are formally launching London Life Sciences Week on the UK stand at the BIO International Convention on Tuesday, 17 June 2025.

In this Q&A blog, BIA spoke to Natasha Gray, Associate & Life Sciences Advisory Service Lead at Warn, a new BIA member.

UK life sciences take centre stage at BIO following a promising Spending Review.

A new residential development in North Cambridge is offering science and technology businesses a ready-made solution to one of the city’s most pressing challenges: housing professional staff within easy reach of major employment hubs.

From a multi-billion-pound boost to R&D and life sciences manufacturing, to scaling innovative businesses through the British Business Bank, the Review signals significant investment.

BIA has released a new explainer highlighting why the UK is well-positioned to lead in functional genomics, thanks to its unparalleled research capacity and exceptional talent pool.

Steve Bates OBE, CEO of the UK BioIndustry Association, responded to the government's Spending Review.

Microbiotica, a clinical-stage biopharma company developing a pipeline of oral precision microbiome medicines called live biotherapeutic products (LBPs), announces that Dr Robert Tansley is appointed Chief Medical Officer with immediate effect.

Discovery Park has launched applications for its immersive business growth programme, ‘Discovery Spark’, seeking early-stage companies in cardiovascular and cardiometabolic health.

PIR International spoke with experienced life science executive, Bob Radie, as part of there BioLeader interview series.

In this blog, Albert Maguire-King, Media and Communications Executive at the BIA, shares his insights on BIA's recent Start-up Festival.

An experienced clinician scientist and surgery consultant, Dr Gianmarco Contino brings deep expertise in gastrointestinal cancers and cancer genomics.

Chancellor Rachel Reeves will announce a transformative £86 billion in the Spending Review to turbo-charge our fastest growing sectors, from tech and life sciences, to advanced manufacturing and defence, as part of the government’s plan to invest in Britain’s renewal through our Modern Industrial Strategy.

Positive news ahead of Spending Review (join our webinar this Friday), latest on getting pensions investment into UK life sciences and more!

In this blog, Kate Barclay, Skills Consultant at BIA, introduces Skills England, a new Executive Agency within the Department for Education.